You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

FLUORODOPA F18 Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Fluorodopa F18 patents expire, and what generic alternatives are available?

Fluorodopa F18 is a drug marketed by Feinstein and is included in one NDA.

The generic ingredient in FLUORODOPA F18 is fluorodopa f-18. One supplier is listed for this compound. Additional details are available on the fluorodopa f-18 profile page.

Summary for FLUORODOPA F18
Drug patent expirations by year for FLUORODOPA F18
Generic Entry Opportunity Date for FLUORODOPA F18
Generic Entry Date for FLUORODOPA F18*:
Constraining patent/regulatory exclusivity:
FDA exclusivity

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLUORODOPA F18

Identify potential brand extensions & 505(b)(2) entrants

Thomas Jefferson UniversityPhase 2
Washington University School of MedicinePhase 1
Erik MittraN/A

See all FLUORODOPA F18 clinical trials

US Patents and Regulatory Information for FLUORODOPA F18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Feinstein FLUORODOPA F18 fluorodopa f-18 SOLUTION;INTRAVENOUS 200655-001 Oct 10, 2019 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.